-
Sanofi Strengthens STAT6 Pipeline with Nurix
Sanofi
Sanofi expands its collaboration with Nurix by licensing NX-3911, a potent STAT6 degrader targeting inflammatory diseases. The deal includes $15M upfront and up to $465M in milestones, with Nurix retaining U.S. co-development rights.
长白|
双牌县|
长乐市|
来安县|
枞阳县|
涞源县|
贞丰县|
博爱县|
东丽区|
井研县|
凌海市|
昆明市|
绥芬河市|
福海县|
株洲县|
通州区|
嘉禾县|
平定县|
盐边县|
根河市|
炎陵县|
志丹县|
侯马市|
上栗县|
儋州市|
青河县|
二连浩特市|
浮山县|
甘南县|
双流县|
金沙县|
沙湾县|
焉耆|
治多县|
吉林省|
闽清县|
延津县|
汉源县|
萨迦县|
洛隆县|
元谋县|